



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

(Under Corporate Insolvency Resolution Process vide Order of Hon'ble NCLT dated 30.08.2018)

Ref: PDL/RKR/Co./2018-19/499

To,

Date: August 14, 2019

The National Stock Exchange of India
Limited
Exchange Plaza, Plot No. C-1, G Block,
Bandra- Kurla Complex, Bandra (E),
Mumbai- 400051

BSE Limited
25th Floor, New Trading Ring,
Rotunda Building,
P.J. Towers, Dalal Street,
Fort Mumbai: 400001

Scrip Code – PARABDRUGS

Scrip Code – 533211

SUBJECT: Audited Quarterly Financial Results for the Quarter ended on June 30, 2019 under Regulation 33 of the SEBI (LODR) Regulations, 2015

Dear Sir/ Ma'am,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Audited Financial Results of Parabolic Drugs Ltd. ("the Company") for the Quarter ended on June 30, 2019.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

Thanking You

Yours Faithfully,

For Parabolic Drugs Ltd

Raj Kumar Ralhan



Raj Kumar Ralhan
Regn. No: IBBI/IPA-001/IP-P00981/2017-2018/11614
Resolution Professional of Parabolic Drugs Limited
Address: Flat No. 801, Tower 01, Kalypso Court, Jaypee Greens Wish Town,
Sector 128, Noida, Uttar Pradesh, 201304
Email: rajkumarralhan@gmail.com



(Under Corporate Insolvency Resolution Process vide Order of Hon'ble NCLT dated 30.08.2018)

Statement of Audited Financial Results for the Quarter ended 30th June 2019
(INR crore)

Sr. No.	Particulars	Quarter ended			Year Ended
		30.06.2019 Unaudited	31.03.2019 Audited	30.06.2018 Audited	31.03.2019 Audited
I	Revenue from Operations				
	(a) Net Sales (Net of Excise duty)	-	-	12.85	17.98
	(b) Other Operating Income	-	-	0.00	0.10
	Total Revenue from Operations (Net of Excise Duty)		-	12.85	18.08
II	Other Income	0.01	-	0.13	0.80
III	Total Income (I + II)	0.01	-	12.98	18.88
IV	Expenses:		-		
	(a) Cost of materials consumed	-	(0.27)	10.31	14.73
	(b) Purchases of Stock-in-Trade	-	-	0.00	0.00
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	0.59	1.20	5.26
	(d) Employees benefits expense	1.09	1.34	1.13	5.34
	(e) Finance Cost	0.16	(0.54)	1.26	3.46
	(f) Depreciation and amortization expense	5.56	5.97	5.73	22.52
	(g) Other expenses	0.86	0.29	5.06	7.50
	Total expenses (IV)	7.67	7.39	24.70	58.82
V	Profit / (Loss) before exceptional and extraordinary items and tax (III-IV)	(7.66)	(7.38)	(11.72)	(39.93)
VI	Exceptional Items	0.00	(1.88)	0.00	(1.88)
VII	Profit / (Loss) before extraordinary items and tax (V - VI)	(7.66)	(9.26)	(11.72)	(41.81)
VII I	Tax expenses:		-		
	(a) Current tax	0.00		0.00	0.00
	(b) Deferred tax	0.17	0.18	(1.20)	(0.41)
IX	Net Profit / (Loss) after tax from	(7.49)	(9.43)	(10.52)	(41.40)

Ray Kumar





PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

(Under Corporate Insolvency Resolution Process vide Order of Hon'ble NCLT dated 30.08.2018)

	Continuing Operations (VII-VIII)				
X	Other Comprehensive Income / (Expense) (Net of Tax)	-	-	0.00	0.00
XI	Total Comprehensive Income / (Expense) (Net of Tax)	(7.49)	(9.43)	(10.52)	(41.40)
XII	Paid-up Equity share capital (Face value of Rs.10/- each)				
	- Issued and Subscribed Capital	61.89	61.89	61.89	61.89
XII I	Earning Per Share (EPS) (Equity shares of Rs. 10/- each fully paid up)				
	a) Basic in Rs.	(1.20)	(1.52)	(1.70)	(6.69)
	b) Diluted in Rs.	(1.20)	(1.40)	(1.70)	(6.69)

Notes

- The company is undergoing Corporate Insolvency Resolution Process ("CIRP") under the provisions of Insolvency and Bankruptcy Code, 2016, pursuant to order dated August 30, 2018, passed by Hon'ble National Company Law Tribunal (NCLT), Chandigarh Bench. In terms of Section 20 of Insolvency Code, the management and operations of the Company are being managed by RP on a Going Concern Basis. *Suspended Board*
- As the powers of the Board of Directors have been suspended, the above results have not been adopted by the Board of Directors. However, the same have been signed by Shri Pranav Gupta, ~~Managing Director~~ of the Company on authorization of RP. These financial results have been thereafter taken on record by the RP on August 14, 2019 for filing with the stock exchanges.
- During the period under review the company has incurred loss owing to the interest burden and economic stress.
- The promoter's shareholding (22619927 Equity Shares) has been pledged pursuant to the terms of CDR package.
- There is not more than one reportable segment i.e. Pharmaceuticals business only hence information as per AS17 is not required to be disclosed.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- During the quarter ended June 30, 2019, most of the lenders have not charged interest due to NPA status of loan accounts. Hence, no provision for interest has been made.

Lay



REGD & Corp office: S.C.O 186-187, 2nd Floor, Sector 8C
Chandigarh- 160 008(India) Tel.: +91-172-3914646.647

Works: Village Sundran, P.O. Mubarnapur, Derubassi,
Distt. Mohali, Punjab, India. Tel: +91-1762-308657
Website: www.parabolichdrugs.com



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

(Under Corporate Insolvency Resolution Process vide Order of Hon'ble NCLT dated 30.08.2018)

Place: Chandigarh

Date: 14.08.2019

For Parabolic Drugs Ltd.

Pranav Gupta
(Managing Director)
DIN No.: _____

Taken on Record



Raj Kumar Ralhan
Resolution Professional of Parabolic Drugs Ltd.
IP Registration No.: IBBI/PA-001/IP-P00981/2017-2018/11614